February 9, 2024, Bengaluru: Karkinos Healthcare and SOPHiA GENETICS (Nasdaq: SOPH) formalised their strategic alliance with the signing of a Memorandum of Understanding (MOU) aimed at transforming the landscape of cancer diagnosis and treatment in India. The partnership will see the two organisations in healthcare and genomics working together to bring revolutionary genomic solutions and data-driven medicine to the forefront of oncology care, particularly focusing on making personalized cancer treatment more accessible.
On this partnership, Dr. Jurgi Camblong, CEO and Co-founder, SOPHiA GENETICS said, “Our collaboration with Karkinos is a monumental occasion that brings together two organizations dedicated to democratizing advanced access to underserved communities. We aim to improve health outcomes for patients by equipping local health organizations with the technology needed to make data-driven decisions.”
Dr. R Venkataramanan, Founder and CEO, Karkinos Healthcare added, “Our alliance with SOPHiA GENETICS is a significant step forward in our mission to democratize advanced cancer care. Through this partnership, we will harness the power of genomics to improve diagnosis, treatment, and management of cancer, especially for the underprivileged and underserved populations in India.”
The partnership will utilize the SOPHiA DDM™ Platform’s capabilities in analysing genomic variants and leveraging artificial intelligence and machine learning algorithms to address rare and complex cancer cases. This will accelerate research and improve the workflow for diagnosing a wide range of cancers, including myeloid cancer, lymphoma, and solid tumors like ovarian, prostate, breast, and lung cancers, among others.
